Abbvie Stock News

First Hawaiian Bank grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,012 shares of the companys stock after purchasing an additional 734 shares during the period. First Hawaiian Banks holdings in AbbVie []

AbbVie (ABBV) has received the European Commissions (EC) approval for interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab) to be used separately or with methotrexate (MTX) The post AbbVies Gets EC Approval for SKYRIZI appeared first on Smarter Analyst .

AbbVie Announces First Provincial Reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for Patients…

Arthur M. Cohen & Associates LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 98.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,230 shares of the company’s stock after selling 254,422 shares during the quarter. Arthur M. Cohen & Associates LLC’s holdings […]

Inspirion Wealth Advisors LLC reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 230,427 shares of the companys stock after selling 583 shares during the period. AbbVie makes up 5.7% of Inspirion Wealth Advisors LLCs investment []

Related Stocks: HD , T , SRUUF , AFRM , PRVA , GLDG , MFMLF , SILEF , MCD , PEP , ENB , ABBV , GDXJ , UBER ,

Probity Advisors Inc. lowered its stake in AbbVie Inc. (NYSE:ABBV) by 3.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,699 shares of the companys stock after selling 758 shares during the quarter. Probity Advisors Inc.s holdings in AbbVie were worth $2,233,000 at the []

Bruton Tyrosine Kinase (BTK) Inhibitors Market Report for Forecast Period 2021-2027: The report presents the prevailing drivers, restraints, opportunities, and current trends in the Bruton Tyrosine Kinase (BTK) Inhibitors industry. The Bruton Tyrosine Kinase (BTK) Inhibitors Market report highlights in-depth

List of Companies profiled in the Report: AbbVie Inc. (Illinois, United States), Novartis AG (Basel, Switzerland), Johnson & Johnson Services, Inc. (New Jersey, United States), Pfizer Inc., (New York, United States), LEO Pharma A/S (Ballerup, Denmark), Merck & Co., Inc. (New Jersey, United States), Amgen Inc. (California, United States), Eli Lilly and Company (Indiana, United States), CELGENE CORPORATION (New Jersey, United States), UCB S.A. (Brussels, Belgium), Sun Pharmaceutical Industries Ltd. (Mumbai, India), Other prominent players List of Companies profiled in the Report: AbbVie Inc. (Illinois, United States), Novartis AG (Basel, Switzerland), Johnson & Johnson Services, Inc. (New Jersey, United States), Pfizer Inc., (New York, United States), LEO Pharma A/S (Ballerup, Denmark), Merck & Co., Inc. (New Jersey, United States), Amgen Inc. (California, United States), Eli Lilly and Company (Indiana, United States), CELGENE CORPORATION (New Jersey, United States), UCB S.A. (Brussels, Belgium), Sun Pharmaceutical Industries Ltd.

Overview of Europe CAR-T Cell Therapy Treatment Market: The primary sources employed while crafting CAR-T Cell Therapy Treatment Market report include the industry experts from the Healthcare industry comprising the management corporation, processing organizations, analytical service suppliers of the industrys value

(RTTNews) - AbbVie (ABBV) announced that the European Union''s European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis. Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with psoriasis. The EC

Related Stocks: LLY , ABBV , GRPH , VINC , KYMR , RUN , PFE , PANW , BMRN , IMTX , OMGA , NKE , MRK , LPSN , VRNS , RACA , BIIB , STTK ,

Ipswich Investment Management Co. Inc. increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 0.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 38,917 shares of the companys stock after purchasing an additional 120 shares during the period. AbbVie makes up 1.1% of Ipswich Investment Management Co. Inc.s portfolio, making the stock []

Related Stocks: HUM , JNJ , ABBV , SIBN , HOLX , BMY , MCK , ATR , AHCO , PKI , BDX , SNY , TMO , HAE , EAR , TRIL , ANTM , FATE ,